Strategic Ownership TearScience has changed ownership multiple times, most notably being acquired by Johnson & Johnson Vision and later by Bausch Health in 2023. This indicates access to a broader ophthalmic distribution network and potential alignment with larger healthcare ecosystems for strategic partnerships or channel expansion.

Meibomian Expertise The core focus on meibomian gland dysfunction (MGD) with patented imaging and treatment technologies (LipiView, LipiScan, LipiFlow) positions the company as a specialized solution in dry eye care. This presents opportunities to upsell to clinics seeking advanced diagnostic and therapeutic capabilities to differentiate their offering.

Clinical Evidence Extensive multicenter, randomized controlled studies support LipiFlow’s safety and effectiveness, reinforcing credibility for reimbursement discussions and payer engagement. This can accelerate pilot programs and clinical adoption in new markets or institutions.

Expansion Readiness Past launches and global reach imply readiness for rapid scale with proper partnerships. Engaging distributors, OEM collaborations, or hospital channel partners could unlock broader geographic and specialty-spanning sales opportunities.

Financial Levers With substantial funding yet modest revenue, there is room for joint marketing or co-development deals, service contracts, and bundled solutions with wider ophthalmic portfolios to accelerate revenue growth and reduce customer acquisition costs.